RxDoctor Payments Data

Holly Becker, APRN

Family · Carlisle, KYNPI 1699154674

Payments from drug & device makers

$1,219in general payments, 2019–2025

Across 67 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$220
  • Teva Pharmaceuticals USA, Inc.$215
  • Lilly USA, LLC$113
  • AstraZeneca$103
  • Novartis$100
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$88
  • plus $380 from 12 others

What the payments were for

  • Food & beverage$1,219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,219 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,680
Medicare patients
40
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$149,208
OzempicSemaglutide86$97,217
JanuviaSitagliptin Phosphate52$64,828
TradjentaLinagliptin28$42,211
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$37,072
EliquisApixaban30$34,853
EntrestoSacubitril/Valsartan17$23,114
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,986
XareltoRivaroxaban12$17,036
ArexvyRsvpref3 Antigen/As01e/Pf45$12,190
ShingrixVaricella-Zoster Ge/As01b/Pf48$9,180
Combivent RespimatIpratropium/Albuterol Sulfate13$7,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,260
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,624
DuleraMometasone/Formoterol11$3,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$25$198,838134 claims
Novo NordiskOzempic, Novolog Mix 70-30$12$99,13697 claims
MerckJanuvia, Dulera$16$68,49963 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$53$58,442127 claims
NovartisEntresto$100$23,11417 claims
AstraZenecaBreztri Aerosphere$103$17,98627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Carlisle

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →